Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives

(2014) M. Heiblig et al.   LEUKEMIA RESEARCH

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

(2013) Jorge E. Cortes et al.   Clinical Lymphoma Myeloma & Leukemia

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

(2013) F. E. Nicolini et al.   HAEMATOLOGICA

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

(2012) H. J. Khoury et al.   BLOOD

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

(2012) H. Kantarjian et al.   BLOOD

Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation

(2012) Marie-Magdelaine Coude et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Omacetaxine as an Anticancer Therapeutic: What is Old is New Again

(2011) Meir Wetzler et al.   CURRENT PHARMACEUTICAL DESIGN

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

(2011) E K Allan et al.   LEUKEMIA

The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge

(2010) Franck E. Nicolini et al.   Clinical Lymphoma Myeloma & Leukemia

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

(2009) S. Soverini et al.   BLOOD

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

(2009) Alfonso Quintás-Cardama et al.   CANCER

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

(2009) Y Chen et al.   LEUKEMIA

Altering Chemosensitivity by Modulating Translation Elongation

(2009) Francis Robert et al.   PLoS One

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

(2008) A. Quintas-Cardama et al.   BLOOD

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

(2008) E. Jabbour et al.   BLOOD